Cryoport (CYRX) Corporate presentation summary

Financial performance and growth

• Q1 FY2026 revenue reached $47.8M, reflecting 16% organic growth year-over-year.

• Updated FY2026 revenue guidance is $192–$196M, with 9–11% organic growth expected.

• Q1 FY2026 gross margin was 46%, up 42bps year-over-year, and adjusted EBITDA improved by $2.2M to $(0.6)M.

• Cash position at Q1 FY2026 was $403.6M, with $185M senior convertible debt due December 2026.

• Double-digit revenue growth across all major segments, including BioServices (+21%), Commercial CGT (+26%), and Life Sciences Services (+15%).

Market position and industry trends

• Holds over 70% share of the CGT clinical trials market, supporting 766 active trials and 21 commercial therapies as of March 2026.

• The CGT commercial market is projected to grow from $10B in 2025 to $38B by 2030.

• Deeply embedded with customers and partners, supporting the majority of leading cell & gene therapy trials and commercial therapies.

• Anticipates up to 10 additional BLA/MAA filings and 8 new therapy approvals in 2026, with 30–50 more CGT approvals by 2030.

• Patient population for CGTs is expected to grow significantly as more treatments are approved.

Platform, services, and technology

• Provides an integrated platform for temperature-controlled supply chain solutions, focusing on cell & gene therapy.

• Core offerings include BioLogistics, IntegriCell®, BioServices, BioStorage, and cryogenic systems.

• End-to-end support covers collection, cryopreservation, manufacturing, storage, packaging, and patient delivery.

• Proprietary Cryoportal® digital platform unifies services, equipment, and data for real-time visibility and predictive analytics.

• Regulatory compliance is ensured through FDA registration, ISO 21973 standards, and GxP-compliant quality systems.